1658TiP The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT). - Padden-Modi, M.; Abdel-Aty, H.; Jones, C.; Brown, L.C.; Dutey-Magni, P.; Yogeswaran, Y.; Horsey, A.; Amos, C.L.; Murray, I.; Hujairi, N.; Tunariu, N.; Millman, R.; et al. (Annals of Oncology, 2024)